MDCO The Medicines Company

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 05 December 2019 Novartis tender offer for The Medicines Company commences

   Basel, December 5, 2019 — Novartis AG (NYSE:NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer

2. 24 November 2019 The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion

   - The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price - Inclisiran, The

3. 24 November 2019 Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

   Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal

4. 18 November 2019 The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing

   - Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH) - ORION-9 further demonstrated

5. 16 November 2019 The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

   - Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10 study affirmed

6. 06 November 2019 The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019

   ORION-10 presentation on November 16 and ORION-9 presentation on November 18 Company also to sponsor educational sessions throughout AHA annual meeting Company to host investor conference call and webcast on

7. 30 October 2019 The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran

   - Inclisiran's pivotal Phase 3 LDL-C lowering clinical trials program successfully completed, and each study met all primary and secondary endpoints - Phase 3 data reinforced durable, potent efficacy and excellent

8. 24 October 2019 The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30

   The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, October 30, 2019 at 8:30 a.m. EDT to discuss its third quarter 2019 financial results and operational developments. The

9. 04 October 2019 The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference

   The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a

10. 25 September 2019 The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients

    ­ ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11 ­ ORION-10 completion marks

11. 25 September 2019 The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

    ­ ORION-9 study met all primary and secondary efficacy endpoints ­ Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where cardiovascular disease is most severe ­

12. 02 September 2019 The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

    -  Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment -  ORION-11 study demonstrates inclisiran's excellent safety profile, including no treatment-related

13. 26 August 2019 The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

    ­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3